Scholar Rock

📍 Cambridge, United States🗓 Founded 2012👥 122 employees💰 Last funded 2013
Biotechnology🌐 scholarrock.com
Website LinkedIn
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced investigational product candidate, apitegromab (SRK-015), a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle, is in development for the treatment of spinal muscular atrophy, or SMA. Following positive results from the TOPAZ Phase 2 trial in patients with Type 2 and Type 3 SMA, we are now advancing apitegromab development through SAPPHIRE, a randomized, double-blind, placebo-controlled, phase 3 clinical trial. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a selective inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2012
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Scholar Rock?
Scholar Rock has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Scholar Rock last raise funding?
The most recent investment in Scholar Rock recorded on gritt.io was in 2013.
When was Scholar Rock founded?
Scholar Rock was founded in 2012.
What industry is Scholar Rock in?
Scholar Rock operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Scholar Rock based?
Scholar Rock is headquartered in Cambridge, United States.